{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:00:57Z","timestamp":1771844457069,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.biomaterials.2023.122280","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T14:44:22Z","timestamp":1692024262000},"page":"122280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Poly-l-glutamic acid modification modulates the bio-nano interface of a therapeutic anti-IGF-1R antibody in prostate cancer"],"prefix":"10.1016","volume":"301","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6184-6147","authenticated-orcid":false,"given":"Sonia","family":"Vicente-Ruiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Armi\u00f1\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9048-9521","authenticated-orcid":false,"given":"Katia","family":"Maso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Gallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0396-4353","authenticated-orcid":false,"given":"Oleksandr","family":"Zagorodko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3645-5192","authenticated-orcid":false,"given":"Julie","family":"Movellan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5334-7786","authenticated-orcid":false,"given":"Fernanda","family":"Rodr\u00edguez-Otorm\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike","family":"Baues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0327-6267","authenticated-orcid":false,"given":"Jan-Niklas","family":"May","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"De Lorenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1090-6805","authenticated-orcid":false,"given":"Twan","family":"Lammers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7771-3373","authenticated-orcid":false,"given":"Mar\u00eda J.","family":"Vicent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2023.122280_bib1","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/2159-8290.CD-13-1010","article-title":"The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis","volume":"4","author":"Lucas","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biomaterials.2023.122280_bib2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10555-013-9482-0","article-title":"Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy","volume":"33","author":"Wu","year":"2014","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.biomaterials.2023.122280_bib3","doi-asserted-by":"crossref","first-page":"16611","DOI":"10.18632\/oncotarget.3425","article-title":"ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents","volume":"6","author":"Mancarella","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biomaterials.2023.122280_bib4","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/annonc\/mds511","article-title":"Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors","volume":"24","author":"Macaulay","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biomaterials.2023.122280_bib5","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1158\/1078-0432.CCR-12-0482","article-title":"A phase II pharmacodynamic study of preoperative figitumumab in patients with localized prostate cancer","volume":"18","author":"Chi","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2023.122280_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.addr.2012.08.012","article-title":"Polymer therapeutics-prospects for 21st century: the end of the beginning","volume":"65","author":"Duncan","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2023.122280_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41573-018-0005-0","article-title":"Polymer\u2013drug conjugate therapeutics: advances, insights and prospects","volume":"18","author":"Ekladious","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2023.122280_bib8","unstructured":"FDA Approved PEGylated Drugs Up To 2021, (n.d.). https:\/\/www.biochempeg.com."},{"key":"10.1016\/j.biomaterials.2023.122280_bib9","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/s41565-021-01001-3","article-title":"The role and impact of polyethylene glycol on anaphylactic reactions to COVID-19 nano-vaccines","volume":"16","author":"Bigini","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biomaterials.2023.122280_bib10","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154\u2013155","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2023.122280_bib11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2020.10.007","article-title":"Therapeutic potential of polypeptide-based conjugates: rational design and analytical tools that can boost clinical translation","volume":"160","author":"Melnyk","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2023.122280_bib12","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1039\/c0py00406e","article-title":"Overcoming the PEG-addiction: well-defined alternatives to PEG, from structure-property relationships to better defined therapeutics","volume":"2","author":"Barz","year":"2011","journal-title":"Polym. Chem."},{"key":"10.1016\/j.biomaterials.2023.122280_bib13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3390\/polym6020515","article-title":"Peptide-based polymer therapeutics","volume":"6","author":"Duro-Castano","year":"2014","journal-title":"Polymers"},{"key":"10.1016\/j.biomaterials.2023.122280_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/wnan.1497","article-title":"A hindsight reflection on the clinical studies of poly(l-glutamic acid)-paclitaxel","volume":"10","author":"Zhao","year":"2018","journal-title":"Wiley Interdiscip. Rev. Nanomedicine Nanobiotechnology."},{"key":"10.1016\/j.biomaterials.2023.122280_bib15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.20892\/j.issn.2095-3941.2017.0099","article-title":"Camptothecin-based nanodrug delivery systems","volume":"14","author":"Wen","year":"2017","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.biomaterials.2023.122280_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biomaterials.2018.09.023","article-title":"Tumor microenvironment-targeted poly-L-glutamic acid-based combination conjugate for enhanced triple negative breast cancer treatment","volume":"186","author":"Arroyo-Crespo","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2023.122280_bib17","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.nano.2016.12.011","article-title":"Use of polymer conjugates for the intraperoxisomal delivery of engineered human alanine:glyoxylate aminotransferase as a protein therapy for primary hyperoxaluria type I","volume":"13","author":"Roncador","year":"2017","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biomaterials.2023.122280_bib18","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1021\/acs.bioconjchem.9b00236","article-title":"Protein PEPylation: a new paradigm of protein-polymer conjugation","volume":"30","author":"Hou","year":"2019","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.biomaterials.2023.122280_bib19","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1021\/bc020019m","article-title":"Multivalent conjugates of poly-\u03b3-D-glutamic acid from Bacillus licheniformis with antibody F(ab') and glycopeptide ligands","volume":"14","author":"Prodhomme","year":"2003","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.biomaterials.2023.122280_bib20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.csbj.2018.10.012","article-title":"Poly-sarcosine and poly(ethylene-glycol) interactions with proteins investigated using molecular dynamics simulations","volume":"16","author":"Settanni","year":"2018","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.biomaterials.2023.122280_bib21","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1021\/acs.bioconjchem.8b00237","article-title":"Polysarcosine as an alternative to PEG for therapeutic protein conjugation","volume":"29","author":"Hu","year":"2018","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.biomaterials.2023.122280_bib22","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1021\/acsnano.9b09213","article-title":"Tuning nanoparticle interactions with ovarian cancer through layer-by-layer modification of surface chemistry","volume":"14","author":"Correa","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2023.122280_bib23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1107\/S0021889812007662","article-title":"New developments in the ATSAS program package for small-angle scattering data analysis","volume":"45","author":"Petoukhov","year":"2012","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.biomaterials.2023.122280_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/micc.12228","article-title":"A retrospective 30 Years after discovery of the enhanced permeability and retention effect of solid tumors: next-generation chemotherapeutics and photodynamic therapy\u2014problems, solutions, and prospects","volume":"23","author":"Maeda","year":"2016","journal-title":"Microcirculation"},{"key":"10.1016\/j.biomaterials.2023.122280_bib25","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1021\/bm5011883","article-title":"Reduction sensitive poly(l-glutamic acid) (PGA)-protein conjugates designed for polymer masked-unmasked protein therapy","volume":"15","author":"Talelli","year":"2014","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.biomaterials.2023.122280_bib26","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC linker chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.biomaterials.2023.122280_bib27","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.18632\/oncotarget.1572","article-title":"Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer","volume":"4","author":"Wyce","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.biomaterials.2023.122280_bib28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41585-019-0178-2","article-title":"Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management","volume":"16","author":"Koo","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.biomaterials.2023.122280_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0027385","article-title":"A computational tool for quantitative analysis of vascular networks","volume":"6","author":"Zudaire","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.biomaterials.2023.122280_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12859-017-1934-z","article-title":"ImageJ2: ImageJ for the next generation of scientific image data","volume":"18","author":"Rueden","year":"2017","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.biomaterials.2023.122280_bib31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.devcel.2015.06.004","article-title":"Mechanisms of vessel pruning and regression","volume":"34","author":"Korn","year":"2015","journal-title":"Dev. Cell"},{"key":"10.1016\/j.biomaterials.2023.122280_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ccr.2011.11.023","article-title":"Rapid decrease in delivery of chemotherapy to tumors after anti-vegf therapy: implications for scheduling of anti-angiogenic drugs","volume":"21","author":"VanderVeldt","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biomaterials.2023.122280_bib33","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biomaterials.2023.122280_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mabi.201600316","article-title":"Polypeptide-based conjugates as therapeutics: opportunities and challenges","volume":"17","author":"Zagorodko","year":"2017","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.biomaterials.2023.122280_bib35","first-page":"522","article-title":"Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?","volume":"31","author":"Aggarwal","year":"2013","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.biomaterials.2023.122280_bib36","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-013-0805-3","article-title":"Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer","volume":"31","author":"Singh","year":"2014","journal-title":"Med. Oncol."},{"key":"10.1016\/j.biomaterials.2023.122280_bib37","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ctrv.2014.07.004","article-title":"Can we unlock the potential of IGF-1R inhibition in cancer therapy?","volume":"40","author":"King","year":"2014","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.biomaterials.2023.122280_bib38","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1074\/jbc.273.8.4672","article-title":"Insulin-like growth factor-I receptor internalization regulates signaling via the Shc\/Mitogen-activated protein kinase pathway, but not the insulin receptor substrate-1 pathway","volume":"273","author":"Chow","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biomaterials.2023.122280_bib39","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1016\/j.ejca.2010.06.005","article-title":"Anti-insulin-like growth factor 1 receptor antibody EM164 (murine AVE1642) exhibits anti-tumour activity alone and in combination with temozolomide against neuroblastoma","volume":"46","author":"Geoerger","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biomaterials.2023.122280_bib40","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.4049\/jimmunol.177.6.4218","article-title":"CD45 neg but not CD45 pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642","volume":"177","author":"Descamps","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.biomaterials.2023.122280_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2015.00064","article-title":"Targeting the IGF-1R: the tale of the tortoise and the hare","volume":"6","author":"Crudden","year":"2015","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biomaterials.2023.122280_bib42","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1021\/mp300293n","article-title":"Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges","volume":"9","author":"Duncan","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biomaterials.2023.122280_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019846","article-title":"IGF1R signaling in Ewing Sarcoma is shaped by clathrin-\/caveolin-dependent endocytosis","volume":"6","author":"Martins","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.biomaterials.2023.122280_bib44","article-title":"Core material and surface chemistry of Layer-by-Layer (LbL) nanoparticles independently direct uptake, transport, and trafficking in preclinical blood-brain barrier (BBB) models","author":"Lamson","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.biomaterials.2023.122280_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2000628","article-title":"SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor","volume":"3","author":"Sehat","year":"2010","journal-title":"Sci. Signal."},{"key":"10.1016\/j.biomaterials.2023.122280_bib46","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2174\/156800907781662248","article-title":"Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase\/akt pathway in prostate cancer","volume":"7","author":"Wang","year":"2007","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.biomaterials.2023.122280_bib47","first-page":"1541","article-title":"Modulation of hypoxia-inducible factor 1\u03b1 expression by the epidermal growth factor\/phosphatidylinositol 3-kinase\/PTEN\/AKT\/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics","volume":"60","author":"Zhong","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2023.122280_bib48","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.cellsig.2007.07.025","article-title":"PI3K\/PTEN\/AKT signaling regulates prostate tumor angiogenesis","volume":"19","author":"Fang","year":"2007","journal-title":"Cell. Signal."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961223002880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961223002880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:28:18Z","timestamp":1758907698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961223002880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":48,"alternative-id":["S0142961223002880"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2023.122280","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poly-l-glutamic acid modification modulates the bio-nano interface of a therapeutic anti-IGF-1R antibody in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2023.122280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"122280"}}